The Nature of Ligand Efficiency

Overview

Journal J Cheminform

Publisher Biomed Central

Specialty Chemistry

Date 2019 Feb 2

PMID 30706294

Citations 28

Authors

Peter W Kenny

Affiliations

Soon will be listed here.

Abstract

Ligand efficiency is a widely used design parameter in drug discovery. It is calculated by scaling affinity by molecular size and has a nontrivial dependency on the concentration unit used to express affinity that stems from the inability of the logarithm function to take dimensioned arguments. Consequently, perception of efficiency varies with the choice of concentration unit and it is argued that the ligand efficiency metric is not physically meaningful nor should it be considered to be a metric. The dependence of ligand efficiency on the concentration unit can be eliminated by defining efficiency in terms of sensitivity of affinity to molecular size and this is illustrated with reference to fragment-to-lead optimizations. Group efficiency and fit quality are also examined in detail from a physicochemical perspective. The importance of examining relationships between affinity and molecular size directly is stressed throughout this study and an alternative to ligand efficiency for normalization of affinity with respect to molecular size is presented.

Citing Articles

Leveraging efficiency metrics for the optimization of CELMoDs™ as cereblon-based molecular glue degraders.

Jia L, Riggs J, Weiss D, Claus B, Shanmugasundaram V, Johnson S RSC Med Chem. 2025; .

PMID: 40047000 PMC: 11876855. DOI: 10.1039/d4md00870g.

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding-based methodology.

Ferla M, Sanchez-Garcia R, Skyner R, Gahbauer S, Taylor J, von Delft F J Cheminform. 2025; 17(1):4.

PMID: 39806443 PMC: 11731148. DOI: 10.1186/s13321-025-00946-0.

compounds: A new avenue for ALR-2 inhibition in diabetes mellitus.

Alshaghdali K, Tasleem M, Rezgui R, Alharazi T, Acar T, Aljerwan R Heliyon. 2024; 10(15):e35255.

PMID: 39170458 PMC: 11336452. DOI: 10.1016/j.heliyon.2024.e35255.

Synthesis, In Silico Study, and In Vitro Antifungal Activity of New 5-(1,3-Diphenyl-1-Pyrazol-4-yl)-4-Tosyl-4,5-Dihydrooxazoles.

Tlapale-Lara N, Lopez J, Gomez E, Villa-Tanaca L, Barrera E, Escalante C Int J Mol Sci. 2024; 25(10).

PMID: 38791130 PMC: 11120875. DOI: 10.3390/ijms25105091.

In silico toxicity and immunological interactions of components of calcium silicate-based and epoxy resin-based endodontic sealers.

Malta C, Barcelos R, Fernandes P, Ortiz Martins M, Sagrillo M, Bier C Clin Oral Investig. 2024; 28(2):148.

PMID: 38353803 DOI: 10.1007/s00784-024-05548-y.

References

Kuntz I, Chen K, Sharp K, Kollman P . The maximal affinity of ligands. Proc Natl Acad Sci U S A. 1999; 96(18):9997-10002. PMC: 17830. DOI: 10.1073/pnas.96.18.9997. View

Teague , Davis , Leeson , Oprea . The Design of Leadlike Combinatorial Libraries. Angew Chem Int Ed Engl. 2000; 38(24):3743-3748. DOI: 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U. View

Boehm H, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W . Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem. 2000; 43(14):2664-74. DOI: 10.1021/jm000017s. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

van de Waterbeemd H, Smith D, Beaumont K, Walker D . Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem. 2001; 44(9):1313-33. DOI: 10.1021/jm000407e. View

Hann M, Leach A, Harper G . Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci. 2001; 41(3):856-64. DOI: 10.1021/ci000403i. View

Oprea T, Davis A, Teague S, Leeson P . Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci. 2001; 41(5):1308-15. DOI: 10.1021/ci010366a. View

Herr R . 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg Med Chem. 2002; 10(11):3379-93. DOI: 10.1016/s0968-0896(02)00239-0. View

McCoy M, Wyss D . Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J Am Chem Soc. 2002; 124(39):11758-63. DOI: 10.1021/ja026166c. View

10.

FREE Jr S, Wilson J . A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. J Med Chem. 1964; 7:395-9. DOI: 10.1021/jm00334a001. View

11.

Congreve M, Carr R, Murray C, Jhoti H . A 'rule of three' for fragment-based lead discovery?. Drug Discov Today. 2003; 8(19):876-7. DOI: 10.1016/s1359-6446(03)02831-9. View

12.

Hopkins A, Groom C, Alex A . Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 2004; 9(10):430-1. DOI: 10.1016/S1359-6446(04)03069-7. View

13.

Bohm H . The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992; 6(1):61-78. DOI: 10.1007/BF00124387. View

14.

Carr R, Congreve M, Murray C, Rees D . Fragment-based lead discovery: leads by design. Drug Discov Today. 2005; 10(14):987-92. DOI: 10.1016/S1359-6446(05)03511-7. View

15.

Verlinde C, Rudenko G, Hol W . In search of new lead compounds for trypanosomiasis drug design: a protein structure-based linked-fragment approach. J Comput Aided Mol Des. 1992; 6(2):131-47. DOI: 10.1007/BF00129424. View

16.

Hopkins A, Mason J, Overington J . Can we rationally design promiscuous drugs?. Curr Opin Struct Biol. 2006; 16(1):127-36. DOI: 10.1016/j.sbi.2006.01.013. View

17.

Jencks W . On the attribution and additivity of binding energies. Proc Natl Acad Sci U S A. 1981; 78(7):4046-50. PMC: 319722. DOI: 10.1073/pnas.78.7.4046. View

18.

Maggiora G . On outliers and activity cliffs--why QSAR often disappoints. J Chem Inf Model. 2006; 46(4):1535. DOI: 10.1021/ci060117s. View

19.

Hajduk P . Fragment-based drug design: how big is too big?. J Med Chem. 2006; 49(24):6972-6. DOI: 10.1021/jm060511h. View

20.

Saxty G, Woodhead S, Berdini V, Davies T, Verdonk M, Wyatt P . Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem. 2007; 50(10):2293-6. DOI: 10.1021/jm070091b. View